-
1
-
-
84904902698
-
EANO guideline on the diagnosis and treatment of anaplastic gliomas and malignant glioblastoma
-
Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline on the diagnosis and treatment of anaplastic gliomas and malignant glioblastoma. Lancet Oncol 2014;15:e395-403.
-
(2014)
Lancet Oncol
, vol.15
, pp. e395-e403
-
-
Weller, M.1
Van Den Bent, M.2
Hopkins, K.3
Tonn, J.C.4
Stupp, R.5
Falini, A.6
-
2
-
-
59949083263
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5.
-
(2009)
J Clin Oncol
, vol.27
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
Duic, P.4
Royce, C.5
Stroud, I.6
-
3
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
Mikkelsen, T.4
Schiff, D.5
Abrey, L.E.6
-
4
-
-
77949891455
-
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
-
Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1168-1174
-
-
Wick, W.1
Puduvalli, V.K.2
Chamberlain, M.C.3
Van Den Bent, M.J.4
Carpentier, A.F.5
Cher, L.M.6
-
5
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
6
-
-
33846149645
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
-
Batchelor TT, Sorensen AG, diTomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
-
(2007)
Cancer Cell
, vol.11
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
DiTomaso, E.3
Zhang, W.T.4
Duda, D.G.5
Cohen, K.S.6
-
7
-
-
19944422751
-
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
-
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
-
(2004)
Cancer Cell
, vol.6
, pp. 553-563
-
-
Winkler, F.1
Kozin, S.V.2
Tong, R.T.3
Chae, S.S.4
Booth, M.F.5
Garkavtsev, I.6
-
8
-
-
84855931910
-
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of antiangiogenic drugs
-
Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of antiangiogenic drugs. Cancer Cell 2012;21:82-91.
-
(2012)
Cancer Cell
, vol.21
, pp. 82-91
-
-
Van Der Veldt, A.A.1
Lubberink, M.2
Bahce, I.3
Walraven, M.4
De Boer, M.P.5
Greuter, H.N.6
-
9
-
-
34748921698
-
Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers
-
Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4033-4042
-
-
Duda, D.G.1
Jain, R.K.2
Willett, C.G.3
-
10
-
-
34547617338
-
Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotherapy
-
Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67:7055-8.
-
(2007)
Cancer Res
, vol.67
, pp. 7055-7058
-
-
Shaked, Y.1
Kerbel, R.S.2
-
11
-
-
0033564974
-
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
-
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
-
(1999)
Cancer Res
, vol.59
, pp. 3374-3378
-
-
Gorski, D.H.1
Beckett, M.A.2
Jaskowiak, N.T.3
Calvin, D.P.4
Mauceri, H.J.5
Salloum, R.M.6
-
12
-
-
33846029123
-
A perivascular niche for brain tumor stem cells
-
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
-
(2007)
Cancer Cell
, vol.11
, pp. 69-82
-
-
Calabrese, C.1
Poppleton, H.2
Kocak, M.3
Hogg, T.L.4
Fuller, C.5
Hamner, B.6
-
13
-
-
34248550985
-
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
-
Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4.
-
(2007)
Cancer Res
, vol.67
, pp. 3560-3564
-
-
Folkins, C.1
Man, S.2
Xu, P.3
Shaked, Y.4
Hicklin, D.J.5
Kerbel, R.S.6
-
14
-
-
79960406166
-
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
-
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011;17:4872-81.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4872-4881
-
-
De Groot, J.F.1
Piao, Y.2
Tran, H.3
Gilbert, M.4
Wu, H.K.5
Liu, J.6
-
15
-
-
84872593848
-
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer
-
Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013;73:539-49.
-
(2013)
Cancer Res
, vol.73
, pp. 539-549
-
-
Terme, M.1
Pernot, S.2
Marcheteau, E.3
Sandoval, F.4
Benhamouda, N.5
Colussi, O.6
-
16
-
-
77955406159
-
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
-
Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80.
-
(2010)
Cancer Res
, vol.70
, pp. 6171-6180
-
-
Shrimali, R.K.1
Yu, Z.2
Theoret, M.R.3
Chinnasamy, D.4
Restifo, N.P.5
Rosenberg, S.A.6
-
17
-
-
77954720781
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
-
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28:2817-23.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2817-2823
-
-
Batchelor, T.T.1
Duda, D.G.2
Di Tomaso, E.3
Ancukiewicz, M.4
Plotkin, S.R.5
Gerstner, E.6
-
18
-
-
66349121063
-
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
-
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-52.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2542-2552
-
-
Kamoun, W.S.1
Ley, C.D.2
Farrar, C.T.3
Duyverman, A.M.4
Lahdenranta, J.5
Lacorre, D.A.6
-
20
-
-
84900989849
-
Bevacizumab for newly diagnosed glioblastoma
-
Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:2049.
-
(2014)
N Engl J Med
, vol.370
, pp. 2049
-
-
Chinot, O.L.1
Wick, W.2
Cloughesy, T.3
-
21
-
-
81155132190
-
Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy
-
Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 2011;71:7021-8.
-
(2011)
Cancer Res
, vol.71
, pp. 7021-7028
-
-
Sitohy, B.1
Nagy, J.A.2
Jaminet, S.C.3
Dvorak, H.F.4
-
22
-
-
84861145421
-
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy
-
DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012;18:2930-42.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2930-2942
-
-
DeLay, M.1
Jahangiri, A.2
Carbonell, W.S.3
Hu, Y.L.4
Tsao, S.5
Tom, M.W.6
-
23
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
-
Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
-
(2005)
Cancer Cell
, vol.8
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
24
-
-
84896739683
-
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
-
Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013;2:49-65.
-
(2013)
CNS Oncol
, vol.2
, pp. 49-65
-
-
Lu, K.V.1
Bergers, G.2
-
25
-
-
66149092730
-
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
-
Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009;106:6742-7.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 6742-6747
-
-
Shojaei, F.1
Wu, X.2
Qu, X.3
Kowanetz, M.4
Yu, L.5
Tan, M.6
-
26
-
-
84868611960
-
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
-
de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, et al. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012;3:1036-48.
-
(2012)
Oncotarget
, vol.3
, pp. 1036-1048
-
-
De Groot, J.1
Liang, J.2
Kong, L.Y.3
Wei, J.4
Piao, Y.5
Fuller, G.6
-
27
-
-
84883009929
-
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition
-
Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013;19:4392-403.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4392-4403
-
-
Piao, Y.1
Liang, J.2
Holmes, L.3
Henry, V.4
Sulman, E.5
De Groot, J.F.6
-
28
-
-
84863754907
-
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
-
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21-35.
-
(2012)
Cancer Cell
, vol.22
, pp. 21-35
-
-
Lu, K.V.1
Chang, J.P.2
Parachoniak, C.A.3
Pandika, M.M.4
Aghi, M.K.5
Meyronet, D.6
-
29
-
-
39849102836
-
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
-
Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20.
-
(2008)
Cancer Cell
, vol.13
, pp. 206-220
-
-
Du, R.1
Lu, K.V.2
Petritsch, C.3
Liu, P.4
Ganss, R.5
Passegue, E.6
-
30
-
-
77952309402
-
Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice
-
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42.
-
(2010)
Neuro Oncol
, vol.12
, pp. 233-242
-
-
De Groot, J.F.1
Fuller, G.2
Kumar, A.J.3
Piao, Y.4
Eterovic, K.5
Ji, Y.6
-
31
-
-
41649112610
-
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
-
Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-87.
-
(2008)
Neurology
, vol.70
, pp. 779-787
-
-
Norden, A.D.1
Young, G.S.2
Setayesh, K.3
Muzikansky, A.4
Klufas, R.5
Ross, G.L.6
-
32
-
-
79951486845
-
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
-
Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-7.
-
(2011)
Neurology
, vol.76
, pp. 432-437
-
-
Pope, W.B.1
Xia, Q.2
Paton, V.E.3
Das, A.4
Hambleton, J.5
Kim, H.J.6
-
33
-
-
79953282797
-
Bevacizumab does not increase the risk of remote relapse in malignant glioma
-
Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69:586-92.
-
(2011)
Ann Neurol
, vol.69
, pp. 586-592
-
-
Wick, A.1
Dorner, N.2
Schafer, N.3
Hofer, S.4
Heiland, S.5
Schemmer, D.6
-
34
-
-
78149492402
-
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
-
Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010;12:855-61.
-
(2010)
Neuro Oncol
, vol.12
, pp. 855-861
-
-
Iwamoto, F.M.1
Lamborn, K.R.2
Robins, H.I.3
Mehta, M.P.4
Chang, S.M.5
Butowski, N.A.6
-
35
-
-
79751535045
-
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
-
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101:57-66.
-
(2011)
J Neurooncol
, vol.101
, pp. 57-66
-
-
Reardon, D.A.1
Vredenburgh, J.J.2
Desjardins, A.3
Peters, K.4
Gururangan, S.5
Sampson, J.H.6
-
36
-
-
84866364645
-
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
-
Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 2012;110:111-8.
-
(2012)
J Neurooncol
, vol.110
, pp. 111-118
-
-
Pan, E.1
Yu, D.2
Yue, B.3
Potthast, L.4
Chowdhary, S.5
Smith, P.6
-
37
-
-
79959841782
-
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing antiepileptic drugs and standard radiation and temozolomide
-
Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing antiepileptic drugs and standard radiation and temozolomide. J Neurooncol 2011;103:325-32.
-
(2011)
J Neurooncol
, vol.103
, pp. 325-332
-
-
Gerstner, E.R.1
Eichler, A.F.2
Plotkin, S.R.3
Drappatz, J.4
Doyle, C.L.5
Xu, L.6
-
38
-
-
72449155176
-
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
-
Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010;46:348-54.
-
(2010)
Eur J Cancer
, vol.46
, pp. 348-354
-
-
Brandes, A.A.1
Stupp, R.2
Hau, P.3
Lacombe, D.4
Gorlia, T.5
Tosoni, A.6
-
39
-
-
77955363593
-
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme
-
Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010;116:3663-9.
-
(2010)
Cancer
, vol.116
, pp. 3663-3669
-
-
Hainsworth, J.D.1
Ervin, T.2
Friedman, E.3
Priego, V.4
Murphy, P.B.5
Clark, B.L.6
-
40
-
-
84869188311
-
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium Study 05-02
-
Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium Study 05-02. Neuro Oncol 2012;14:1511-8.
-
(2012)
Neuro Oncol
, vol.14
, pp. 1511-1518
-
-
Lee, E.Q.1
Kuhn, J.2
Lamborn, K.R.3
Abrey, L.4
DeAngelis, L.M.5
Lieberman, F.6
-
41
-
-
84869155416
-
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
-
Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 2012;14:1519-26.
-
(2012)
Neuro Oncol
, vol.14
, pp. 1519-1526
-
-
Kreisl, T.N.1
McNeill, K.A.2
Sul, J.3
Iwamoto, F.M.4
Shih, J.5
Fine, H.A.6
-
42
-
-
84871816644
-
Continuous daily sunitinib for recurrent glioblastoma
-
Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 2013;111:41-8.
-
(2013)
J Neurooncol
, vol.111
, pp. 41-48
-
-
Kreisl, T.N.1
Smith, P.2
Sul, J.3
Salgado, C.4
Iwamoto, F.M.5
Shih, J.H.6
-
43
-
-
77955922743
-
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
-
Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010;78:85-90.
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.78
, pp. 85-90
-
-
Drappatz, J.1
Norden, A.D.2
Wong, E.T.3
Doherty, L.M.4
Lafrankie, D.C.5
Ciampa, A.6
-
44
-
-
65649146868
-
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
-
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009;115:2188-98.
-
(2009)
Cancer
, vol.115
, pp. 2188-2198
-
-
Reardon, D.A.1
Egorin, M.J.2
Desjardins, A.3
Vredenburgh, J.J.4
Beumer, J.H.5
Lagattuta, T.F.6
-
45
-
-
84863796631
-
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
-
Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 2012;69:1507-18.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1507-1518
-
-
Reardon, D.A.1
Conrad, C.A.2
Cloughesy, T.3
Prados, M.D.4
Friedman, H.S.5
Aldape, K.D.6
-
46
-
-
82955232920
-
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
-
Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 2011;105:621-7.
-
(2011)
J Neurooncol
, vol.105
, pp. 621-627
-
-
Reardon, D.A.1
Vredenburgh, J.J.2
Coan, A.3
Desjardins, A.4
Peters, K.B.5
Gururangan, S.6
-
47
-
-
84874038379
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
-
Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 2013;19:900-8.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 900-908
-
-
Reardon, D.A.1
Groves, M.D.2
Wen, P.Y.3
Nabors, L.4
Mikkelsen, T.5
Rosenfeld, S.6
-
48
-
-
84879300467
-
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
-
Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 2013;111:205-12.
-
(2013)
J Neurooncol
, vol.111
, pp. 205-212
-
-
Muhic, A.1
Poulsen, H.S.2
Sorensen, M.3
Grunnet, K.4
Lassen, U.5
-
49
-
-
79960111080
-
Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study
-
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29:2689-95.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2689-2695
-
-
De Groot, J.F.1
Lamborn, K.R.2
Chang, S.M.3
Gilbert, M.R.4
Cloughesy, T.F.5
Aldape, K.6
-
50
-
-
75449088610
-
FDA drug approval summary: Bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme
-
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8.
-
(2009)
Oncologist
, vol.14
, pp. 1131-1138
-
-
Cohen, M.H.1
Shen, Y.L.2
Keegan, P.3
Pazdur, R.4
-
51
-
-
77951648711
-
Bevacizumab and recurrent malignant gliomas: A European perspective
-
author reply e190-2
-
Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010;28:e188-9; author reply e190-2.
-
(2010)
J Clin Oncol
, vol.28
, pp. e188-e189
-
-
Wick, W.1
Weller, M.2
Van Den Bent, M.3
Stupp, R.4
-
52
-
-
77953872335
-
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
-
Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 2010;17:970-4.
-
(2010)
J Clin Neurosci
, vol.17
, pp. 970-974
-
-
Francesconi, A.B.1
Dupre, S.2
Matos, M.3
Martin, D.4
Hughes, B.G.5
Wyld, D.K.6
-
53
-
-
84861312289
-
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma
-
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2012;107:155-64.
-
(2012)
J Neurooncol
, vol.107
, pp. 155-164
-
-
Reardon, D.A.1
Desjardins, A.2
Peters, K.B.3
Gururangan, S.4
Sampson, J.H.5
McLendon, R.E.6
-
54
-
-
71649094684
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study
-
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009;101:1986-94.
-
(2009)
Br J Cancer
, vol.101
, pp. 1986-1994
-
-
Reardon, D.A.1
Desjardins, A.2
Vredenburgh, J.J.3
Gururangan, S.4
Sampson, J.H.5
Sathornsumetee, S.6
-
55
-
-
51449122032
-
Bevacizumab and irinotecan therapy in glioblastoma multiforme: A series of 13 cases
-
Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet M, Rahman M, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 2008;109:268-72.
-
(2008)
J Neurosurg
, vol.109
, pp. 268-272
-
-
Ali, S.A.1
McHayleh, W.M.2
Ahmad, A.3
Sehgal, R.4
Braffet, M.5
Rahman, M.6
-
56
-
-
43049124382
-
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
-
Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-73.
-
(2008)
Cancer
, vol.112
, pp. 2267-2273
-
-
Bokstein, F.1
Shpigel, S.2
Blumenthal, D.T.3
-
57
-
-
46949103217
-
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
-
Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 2008;89:113-8.
-
(2008)
J Neurooncol
, vol.89
, pp. 113-118
-
-
Kang, T.Y.1
Jin, T.2
Elinzano, H.3
Peereboom, D.4
-
58
-
-
58149456505
-
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
-
Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-36.
-
(2009)
J Neurooncol
, vol.91
, pp. 329-336
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
Anderson, J.4
Doyle, T.5
Ellika, S.6
-
59
-
-
77954712620
-
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumaband irinotecan
-
Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumaband irinotecan. APMIS 2010;118:585-94.
-
(2010)
APMIS
, vol.118
, pp. 585-594
-
-
Hasselbalch, B.1
Eriksen, J.G.2
Broholm, H.3
Christensen, I.J.4
Grunnet, K.5
Horsman, M.R.6
-
60
-
-
65249185501
-
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
-
Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-22.
-
(2009)
Neurology
, vol.72
, pp. 1217-1222
-
-
Nghiemphu, P.L.1
Liu, W.2
Lee, Y.3
Than, T.4
Graham, C.5
Lai, A.6
-
61
-
-
84857373272
-
Bevacizumab and daily temozolomide for recurrent glioblastoma
-
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012;118:1302-12.
-
(2012)
Cancer
, vol.118
, pp. 1302-1312
-
-
Desjardins, A.1
Reardon, D.A.2
Coan, A.3
Marcello, J.4
Herndon, J.E.5
Bailey, L.6
-
62
-
-
78650102866
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
-
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12:1300-10.
-
(2010)
Neuro Oncol
, vol.12
, pp. 1300-1310
-
-
Sathornsumetee, S.1
Desjardins, A.2
Vredenburgh, J.J.3
McLendon, R.E.4
Marcello, J.5
Herndon, J.E.6
-
63
-
-
84883474833
-
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): A north central cancer treatment group trial
-
Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 2013;19:4816-23.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4816-4823
-
-
Galanis, E.1
Anderson, S.K.2
Lafky, J.M.3
Uhm, J.H.4
Giannini, C.5
Kumar, S.K.6
-
64
-
-
84861696508
-
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
-
Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012;107:133-8.
-
(2012)
J Neurooncol
, vol.107
, pp. 133-138
-
-
Drappatz, J.1
Lee, E.Q.2
Hammond, S.3
Grimm, S.A.4
Norden, A.D.5
Beroukhim, R.6
-
65
-
-
84858701148
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas
-
Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2012;82:2018-24.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
, pp. 2018-2024
-
-
Cuneo, K.C.1
Vredenburgh, J.J.2
Sampson, J.H.3
Reardon, D.A.4
Desjardins, A.5
Peters, K.B.6
-
66
-
-
68649114787
-
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
-
Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.75
, pp. 156-163
-
-
Gutin, P.H.1
Iwamoto, F.M.2
Beal, K.3
Mohile, N.A.4
Karimi, S.5
Hou, B.L.6
-
67
-
-
84863210362
-
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme
-
Cabrera AR, Cuneo KC, Vredenburgh JJ, Sampson JH, Kirkpatrick JP. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw 2012;10:695-9.
-
(2012)
J Natl Compr Canc Netw
, vol.10
, pp. 695-699
-
-
Cabrera, A.R.1
Cuneo, K.C.2
Vredenburgh, J.J.3
Sampson, J.H.4
Kirkpatrick, J.P.5
-
68
-
-
84904913239
-
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial
-
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53.
-
(2014)
Lancet Oncol
, vol.15
, pp. 943-953
-
-
Taal, W.1
Oosterkamp, H.M.2
Walenkamp, A.M.3
Dubbink, H.J.4
Beerepoot, L.V.5
Hanse, M.C.6
-
69
-
-
79959812904
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
-
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011;103:371-9.
-
(2011)
J Neurooncol
, vol.103
, pp. 371-379
-
-
Reardon, D.A.1
Desjardins, A.2
Peters, K.3
Gururangan, S.4
Sampson, J.5
Rich, J.N.6
-
70
-
-
80052749324
-
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
-
Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 2011;104:287-91.
-
(2011)
J Neurooncol
, vol.104
, pp. 287-291
-
-
Lu-Emerson, C.1
Norden, A.D.2
Drappatz, J.3
Quant, E.C.4
Beroukhim, R.5
Ciampa, A.S.6
-
71
-
-
70350142397
-
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
-
Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6.
-
(2009)
Neurology
, vol.73
, pp. 1200-1206
-
-
Iwamoto, F.M.1
Abrey, L.E.2
Beal, K.3
Gutin, P.H.4
Rosenblum, M.K.5
Reuter, V.E.6
-
72
-
-
67649092660
-
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
-
Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11:550-5.
-
(2009)
Neuro Oncol
, vol.11
, pp. 550-555
-
-
Quant, E.C.1
Norden, A.D.2
Drappatz, J.3
Muzikansky, A.4
Doherty, L.5
Lafrankie, D.6
-
73
-
-
84867900118
-
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
-
Reardon DA, Herndon JE II, Peters KB, Desjardins A, Coan A, Lou E, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 2012;107:1481-7.
-
(2012)
Br J Cancer
, vol.107
, pp. 1481-1487
-
-
Reardon, D.A.1
Herndon, J.E.2
Peters, K.B.3
Desjardins, A.4
Coan, A.5
Lou, E.6
-
74
-
-
79951984402
-
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
-
Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142-8.
-
(2011)
J Clin Oncol
, vol.29
, pp. 142-148
-
-
Lai, A.1
Tran, A.2
Nghiemphu, P.L.3
Pope, W.B.4
Solis, O.E.5
Selch, M.6
-
75
-
-
83955165997
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
-
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;82:58-66.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
, pp. 58-66
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Kirkpatrick, J.P.3
Reardon, D.A.4
Peters, K.B.5
Herndon, J.E.6
-
76
-
-
79959213028
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma
-
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011;17:4119-24.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4119-4124
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Reardon, D.A.3
Peters, K.B.4
Herndon, J.E.5
Marcello, J.6
-
77
-
-
84894194756
-
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
-
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
-
(2014)
N Engl J Med
, vol.370
, pp. 709-722
-
-
Chinot, O.L.1
Wick, W.2
Mason, W.3
Henriksson, R.4
Saran, F.5
Nishikawa, R.6
-
78
-
-
84894114159
-
A randomized trial of bevacizumab for newly diagnosed glioblastoma
-
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
-
(2014)
N Engl J Med
, vol.370
, pp. 699-708
-
-
Gilbert, M.R.1
Dignam, J.J.2
Armstrong, T.S.3
Wefel, J.S.4
Blumenthal, D.T.5
Vogelbaum, M.A.6
-
80
-
-
77951625266
-
Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
-
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1963-1972
-
-
Wen, P.Y.1
Macdonald, D.R.2
Reardon, D.A.3
Cloughesy, T.F.4
Sorensen, A.G.5
Galanis, E.6
-
81
-
-
84898748271
-
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM)
-
Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31:(suppl; abstr LBA2010).
-
(2013)
J Clin Oncol
, vol.31
-
-
Sulman, E.P.1
Won, M.2
Blumenthal, D.T.3
Vogelbaum, M.A.4
Colman, H.5
Jenkins, R.B.6
-
82
-
-
33644820339
-
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
-
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
-
(2006)
Cancer Cell
, vol.9
, pp. 157-173
-
-
Phillips, H.S.1
Kharbanda, S.2
Chen, R.3
Forrest, W.F.4
Soriano, R.H.5
Wu, T.D.6
-
83
-
-
84891785971
-
Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial
-
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4085-4091
-
-
Gilbert, M.R.1
Wang, M.2
Aldape, K.D.3
Stupp, R.4
Hegi, M.E.5
Jaeckle, K.A.6
-
84
-
-
38349155463
-
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
-
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 271-278
-
-
Sathornsumetee, S.1
Cao, Y.2
Marcello, J.E.3
Herndon, J.E.4
McLendon, R.E.5
Desjardins, A.6
-
85
-
-
84907510882
-
Correlations of molecular subtypes with survival in AVAglio (bevacizumab [BV] plus radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GBM])
-
Phillips H, Sandmann T, Li C, Cloughesy T, Chinot O, Wick W, et al. Correlations of molecular subtypes with survival in AVAglio (bevacizumab [BV] plus radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GBM]). J Clin Oncol 2014;32:5s.(suppl; abstr 2001).
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Phillips, H.1
Sandmann, T.2
Li, C.3
Cloughesy, T.4
Chinot, O.5
Wick, W.6
-
86
-
-
84887419886
-
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
-
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013;110:19059-64.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 19059-19064
-
-
Batchelor, T.T.1
Gerstner, E.R.2
Emblem, K.E.3
Duda, D.G.4
Kalpathy-Cramer, J.5
Snuderl, M.6
-
87
-
-
84918566143
-
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)
-
Nishikawa R, Saran F, Mason W, Wick W, Cloughesy TF, Henriksson R, et al. Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31: (suppl; abstr 2023).
-
(2013)
J Clin Oncol
, vol.31
-
-
Nishikawa, R.1
Saran, F.2
Mason, W.3
Wick, W.4
Cloughesy, T.F.5
Henriksson, R.6
-
88
-
-
84894246282
-
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
-
Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 2014;16:392-9.
-
(2014)
Neuro Oncol
, vol.16
, pp. 392-399
-
-
Tabouret, E.1
Boudouresque, F.2
Barrie, M.3
Matta, M.4
Boucard, C.5
Loundou, A.6
-
89
-
-
77954991606
-
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
-
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010;15:577-83.
-
(2010)
Oncologist
, vol.15
, pp. 577-583
-
-
Duda, D.G.1
Willett, C.G.2
Ancukiewicz, M.3
Di Tomaso, E.4
Shah, M.5
Czito, B.G.6
-
90
-
-
67650075305
-
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment
-
Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-9.
-
(2009)
Radiology
, vol.252
, pp. 182-189
-
-
Pope, W.B.1
Kim, H.J.2
Huo, J.3
Alger, J.4
Brown, M.S.5
Gjertson, D.6
-
91
-
-
70350010318
-
Quantitative imaging biomarkers in neuro-oncology
-
Waldman AD, Jackson A, Price SJ, Clark CA, Booth TC, Auer DP, et al. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 2009;6:445-54.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 445-454
-
-
Waldman, A.D.1
Jackson, A.2
Price, S.J.3
Clark, C.A.4
Booth, T.C.5
Auer, D.P.6
-
92
-
-
84857915848
-
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
-
O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012;9:167-77.
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 167-177
-
-
O'Connor, J.P.1
Jackson, A.2
Parker, G.J.3
Roberts, C.4
Jayson, G.C.5
-
93
-
-
84883760198
-
Vessel architectural imaging identifi es cancer patient responders to anti-angiogenic therapy
-
Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, et al. Vessel architectural imaging identifi es cancer patient responders to anti-angiogenic therapy. Nat Med 2013;19:1178-83.
-
(2013)
Nat Med
, vol.19
, pp. 1178-1183
-
-
Emblem, K.E.1
Mouridsen, K.2
Bjornerud, A.3
Farrar, C.T.4
Jennings, D.5
Borra, R.J.6
-
94
-
-
36048955738
-
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
-
Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4714-4721
-
-
Chen, W.1
Delaloye, S.2
Silverman, D.H.3
Geist, C.4
Czernin, J.5
Sayre, J.6
-
95
-
-
84864683637
-
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab
-
Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, et al. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 2012;14:1079-89.
-
(2012)
Neuro Oncol
, vol.14
, pp. 1079-1089
-
-
Harris, R.J.1
Cloughesy, T.F.2
Pope, W.B.3
Nghiemphu, P.L.4
Lai, A.5
Zaw, T.6
-
96
-
-
84860487114
-
Phase 2 trial design in neuro-oncology revisited: A report from the RANO group
-
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol 2012;13:e196-204.
-
(2012)
Lancet Oncol
, vol.13
, pp. e196-e204
-
-
Galanis, E.1
Wu, W.2
Cloughesy, T.3
Lamborn, K.4
Mann, B.5
Wen, P.Y.6
-
97
-
-
84887116872
-
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
-
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212-8.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3212-3218
-
-
Batchelor, T.T.1
Mulholland, P.2
Neyns, B.3
Nabors, L.B.4
Campone, M.5
Wick, A.6
-
98
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
-
(2005)
Science
, vol.307
, pp. 58-62
-
-
Jain, R.K.1
|